Oncogenic Ras-induced morphologic change is through MEK/ERK signaling pathway to downregulate stat3 at a posttranslational level in NIH3T3 cells

Neoplasia

Volumn 10, Issue 1, 2008, Pages 52-60

  Yeh, Hsuan Heng ^a   Wu, Chin Han ^a   Giri, Raghavaraju ^a   Kato, Ken ^b   Kohno, Kimitoshi ^b   Izumi, Hiroto ^b   Chou, Cheng Yang ^a   Su, Wu Chou ^a,c   Liu, Hsiao Sheng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

EID: 38649121484     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07691     Document Type: Article

References (33)

1. Takai Y, Sasaki T, and Matozaki T (2001). Small GTP-binding proteins. Physiol Rev 81, 153-208.
2. Leevers SJ, Paterson HF, and Marshall CJ (1994). Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411-414.
3. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, and Downward J (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532.
4. Kelley GG, Reks SE, Ondrako JM, and Smrcka AV (2001). Phospholipase C (epsilon): a novel Ras effector. EMBO J 20, 743-754.
5. Harrison RE and Turley EA (2001). Active ERK regulates microtubule stability in H-ras-transformed cells. Neoplasia 3, 385-394.
6. Gluck U, Kwiatkowski DJ, and Ben-Ze'ev A (1993). Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-actinin cDNA. Proc Natl Acad Sci USA 90, 383-387.
7. Rodriguez Fernandez JL, Geiger B, Salomon D, Sabanay I, Zoller M, and Ben-Ze'ev A (1992). Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol 119, 427-438.
8. Janssen RA, Kim PN, Mier JW, and Morrison DK (2003). Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts. Mol Cell Biol 23, 1786-1797.
9. Shields JM, Pruitt K, McFall A, Shaub A, and Der CJ (2000). Understanding Ras: "it ain't over 'til it's over". Trends Cell Biol 10, 147-154.
10. Yu H and Jove R (2004). The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4, 97-105.
11. Buettner R, Mora LB, and Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945-954.
12. Levy DE and Darnell JE Jr (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3, 651-662.
13. Silver DL and Montell DJ (2001). Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in Drosophila. Cell 107, 831-841.
14. Yamashita S, Miyagi C, Carmany-Rampey A, Shimizu T, Fujii R, Schier AF, and Hirano T (2002). Stat3 controls cell movements during zebrafish gastrulation. Dev Cell 2, 363-375.
15. Guerrero S, Figueras A, Casanova I, Farre L, Lloveras B, Capella G, Trias M, and Mangues R (2002). Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 16, 1642-1644.
16. Silver DL, Naora H, Liu J, Cheng W, and Montell DJ (2004). Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64, 3550-3558.
17. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, and Cao X (2006). Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 172, 245-257.
18. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell JE Jr (1999). Stat3 as an oncogene. Cell 98, 295-303.
19. Kato K, Nomoto M, Izumi H, Ise T, Nakano S, Niho Y, and Kohno K (2000). Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. Biochim Biophys Acta 1493, 91-100.
20. Liu HS, Chen CY, Lee CH, and Chou YI (1998). Selective activation of oncogenic Ha-ras-induced apoptosis in NIH/3T3 cells. Br J Cancer 77, 1777-1786.
21. Yeh HH, Lai WW, Chen HH, Liu HS, and Su WC (2006). Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25, 4300-4309.
22. Chang TY, Wen YY, Yeh HH, Wang ST, Su IJ, and Liu HS (1999). Plasmid harboring lac repressor and tTA activator genes can regulate two inducible genes in mammalian cells. Biotechniques 27, 466-469.
23. Spencer VA and Davie JR (2000). Signal transduction pathways and chromatin structure in cancer cells. J Cell Biochem Suppl Suppl 35, 27-35.
24. Hurlin PJ, Maher VM, and McCormick JJ (1989). Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene. Proc Natl Acad Sci USA 86, 187-191.
25. Kwon HJ, Owa T, Hassig CA, Shimada J, and Schreiber SL (1998). Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 95, 3356-3361.
26. Cowley S, Paterson H, Kemp P, and Marshall CJ (1994). Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852.
27. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, and Ahn NG (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970.
28. Fukazawa H and Uehara Y (2000). U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res 60, 2104-2107.
29. Kira M, Sano S, Takagi S, Yoshikawa K, Takeda J, and Itami S (2002). STAT3 deficiency in keratinocytes leads to compromised cell migration through hyperphosphorylation of p130(cas). J Biol Chem 277, 12931-12936.
30. Suzuki N, Del Villar K, and Tamanoi F (1998). Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci USA 95, 10499-10504.
31. Lovric J, Dammeier S, Kieser A, Mischak H, and Kolch W (1998). Activated raf induces the hyperphosphorylation of stathmin and the reorganization of the microtubule network. J Biol Chem 273, 22848-22855.
32. Lornejad-Schafer M, Albrecht U, Poppek D, Gehrmann T, Grune T, Bode JG, Haussinger D, and Schliess F (2005). Osmotic regulation of STAT3 stability in H4IIE rat hepatoma cells. FEBS Lett 579, 5791-5797.
33. Daino H, Matsumura I, Takada K, Odajima J, Tanaka H, Ueda S, Shibayama H, Ikeda H, Hibi M, Machii T, et al. (2000). Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood 95, 2577-2585.